Snell & Wilmer Advises San Diego-Based Medical Device Company Octet Medical, Inc. As It Secures $10M in Series B Financing

SAN DIEGO – Snell & Wilmer advised Octet Medical, Inc. (Octet), private medical device firm as it secured $10M in Series B financing which follows Octet’s $6M Series A financing, bringing the total capital raised to $16.8M. The Series B investment is projected to enable Octet to advance the development of the Octet Medical Electrostatic Applicator (OMEA) for use in clinical trial programs.

“The OMEA electrostatic sprayer with interchangeable single use disposable product cartridges will reshape how clinicians apply topical therapeutics,” said Bud Brainerd, the CEO of Octet in a recent press release, “The Series B round will enable our team to advance the production of the existing OMEA prototypes into units that can be used in clinical trial programs.”

Bardia Moayedi led the Snell & Wilmer team advising Octet. The diverse team included Sarah Hibbard, Christopher Franich, and Paralegal Scott Drake.  

Snell & Wilmer's corporate and securities attorneys have served as counsel to a substantial number of clients ranging from Fortune 100 companies to smaller emerging businesses. Our attorneys have provided sophisticated legal representation to biotech companies, health care and financial institutions, public utilities, homebuilders, transportation companies, restaurant and hospitality providers, athletic complexes, fitness facilities, and many other types of businesses. Snell & Wilmer’s venture capital and private equity practice covers multiple aspects of the transactional arena involving public and private companies, including the structuring and execution of majority buyouts and minority investments, acquisitions (including buy- and sell-side deals, as well as negotiated and auction deals), financings (including 144A transactions and PIPEs), going-private transactions, and spin-off transactions. Our venture capital and private equity attorneys advise both domestic and international funds, including venture capital, private equity, hedge, mezzanine, real estate opportunity, fund-of-funds, exchange, and other private investment funds.